Alnylam Pharmaceuticals (ALNY) Invested Capital (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has 18 years of Invested Capital data on file, last reported at $1.1 billion in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital rose 97.59% year-over-year to $1.1 billion; the trailing twelve-month figure through Mar 2026 stood at $1.1 billion (up 97.59% YoY), and the FY2025 full-year result was $789.2 million, up 390.51% from the prior year.
• Invested Capital for Q1 2026 stood at $1.1 billion, up from $789.2 million in the prior quarter.
• Across five years, Invested Capital topped out at $1.1 billion in Q1 2022 and bottomed at -$408.1 million in Q2 2023.
• The 5-year median for Invested Capital is $32.4 million (2024), against an average of $221.1 million.
• The widest annual swing landed in 2023, when Invested Capital tumbled 147.8%; it then jumped 12209.26% in 2025.
• A 5-year view of Invested Capital shows it stood at -$158.2 million in 2022, then sank by 39.45% to -$220.6 million in 2023, then surged by 172.92% to $160.9 million in 2024, then jumped by 390.51% to $789.2 million in 2025, then surged by 36.27% to $1.1 billion in 2026.
• The last three Invested Capital figures came in at $1.1 billion (Q1 2026), $789.2 million (Q4 2025), and $355.2 million (Q3 2025), per Business Quant data.

Peer Comparison